Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma

Journal of the American Academy of Dermatology

Volumn 36, Issue 6 I, 1997, Pages 950-955

  Greiner, D ^a   Olsen, E A ^a   Petroni, G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOSTATIN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN LYMPHOMA; T CELL LYMPHOMA; VERTIGO;

EID: 0030917991     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(97)80279-4     Document Type: Article

References (25)

1. Bunn P.A. Hoffman S.J. Norris D. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome) Ann Intern Med 121 1994 592 602
2. Kaye F.J. Bunn P.A. Steinberg S.M. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides N Engl J Med 321 1989 1784 1790
3. Grever M.R. Siaw M.F.E. Jacob W.F. The biochemical and clinical consequences of 2′-deoxycofonnycin in refractory lymphoproliferative malignancy Blood 57 1981 406 417
4. De Korte D. Haverkort W.A. Van Leeuwen E.F. Biochemical consequences of 2′-deoxycofonnycin treatment in a patient with T-cell lymphoma Cancer 60 1987 750 755
5. Major P.P.K. Agarwal R.P. Kufe D.W. Clinical phannacology of deoxycoformycin Blood 58 1 1981 91 96
6. Cheson B.D. The purine analogs: a therapeutic beauty contest J Clin Oncol 10 1992 868 871
7. Cummings F.J. Kim K. Neiman R.S. Phase It trial of pentostatin in refractory lymphomas and cutaneous T-cell disease J Clin Oncol 9 1991 565 571
8. Grever M.R. Bisaccia E. Scarborough D.A. An investigation of 2′-deoxycoformycm in the treatment of cutaneous T-cell lymphoma Blood 61 1983 279 282
9. Grever M.R. Leiby J.M. Kraut E.H. Low-dose deoxycoformycin in lymphoid malignancy J Clin Oncol 3 1985 1196 1201
10. Mercieca J. Matutes E. Dearden C. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype J Clin Oncol 12 1994 2588 2593
11. Ho A.D. Thaler J. Willemze R. Pentostatin (2′-deox-ycoformycin) for the treatment of lymphoid neoplasms. Cancer Treat Rev 17 1990 213 215
12. O'Dwyer P.J. Wagner B. Leyland-Jones B. 2′-Deox-ycoformycin (pentostatin) for lymphoid malignancies Ann Intern Med 108 1989 733 743
13. Spiers A.S.D. The role of pentostatin (2′-deoxycoformycin, dCF) in the mauagement of lymphoproliferative malignancies Blood Rev 1 1987 106 110
14. Dang-Vu A.P. Olsen E.A. Vollmer R.T. Treatment of cutaneous T-cell lymphoma with 2′-deoxycoformycin (pentostatin) J Am Acad Dermatol 19 1988 692 698
15. Bunn P.A. Lamberg S.I. Report of a committee on staging and classification of cutaneous T-cell lymphoma Cancer Treat 68 1979 726 727
16. Brogden R.N. Sorkin E. Pentostatin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders Drugs 46 1993 652 677
17. Lee N. Russell N. Ganeshaguru K. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase Br J Haematol 56 1984 107 119
18. Saven A. Prio L.D. The newer purine analogs Cancer 72 1993 3470 3483
19. Dearden C. Matures E. Catovsky D. Deoxycoformycin in the treatment of mature T-cell lymphomas Br J Cancer 64 1991 903 906
20. Kanofsky J.R. Roth D.G. Smyth J.F. Treatment of lymphoid malignancies with 2′deoxycoformycin Am J Clin Oncol 5 1982 179 183
21. Klohs W.D. Kraker A.J. Pentostatin: future directions Pharmacol Rev 44 1992 459 477
22. Saven A. Piro I.D. Newer purine analogues for the treatment of hairy-cell leukemia N Engl J Med 330 1994 691 697
23. Seto S. Carrera C.J. Kubota M. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosme toxicity to nondividing human lymphocytes J Clin Invest 75 1985 377 383
24. Murphy S.B. Herrod H.G. Sinkule J.A. Severe combined immunodeficiency and profound weight loss associated with chronic intermittent administration of 2′-deoxycoformycin Cancer Treat 2 1984 63 66
25. Kim Y.A. Bishop U. Vanhese A. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome Arch Dermatol 131 1995 1003 1008